NuTide:121 will compare NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients with Advanced Biliary Tract Cancer.
The study opened to recruitment in December 2019 and will enrol up to 828 patients globally. There will be a number of UK sites be participating.
(The NUC-1031 Plus Cisplatin combination was developed through the UK ABC-08 study)
NuTide:121 is open and recruiting at the following sites:
|Palmer, Daniel||The Clatterbridge Cancer Centre|
|Valle, Juan||The Christie|
|Ross, Paul||Guy’s Hospital|
|Braconi, Chiara||Beatson West of Scotland Cancer Centre|
|Christie, Alan||Western General Hospital|
|Rees, Charlotte||Southampton General Hospital – due to open at this site during 2020|